Recall MonitorBlood pressure medication recalls in CanadaSartans, amlodipine and the impurity recalls that keep coming back
Updated September 2026 · Sourced from Health Canada
According to Statistics Canada, about one in four Canadian adults is diagnosed with high blood pressure. These are daily, long-term maintenance medications — which is precisely why impurity recalls matter so deeply: exposure accumulates over months or years.
Health Canada has already logged 71 pharmaceutical drug recalls so far in 2026, and blood pressure medications remain among the most consistently affected categories.
Recall Monitor emails or texts you the day Canada issues a recall that matches what you watch, often days before the news covers it, if it does at all.
Sartan and amlodipine lots were recalled again in 2026 — most patients found out from the pharmacy, weeks later.
2018: valsartan and the class action
In July 2018, Health Canada launched urgent recalls of valsartan products after active pharmaceutical ingredients manufactured by overseas suppliers were found contaminated with N-nitrosodimethylamine (NDMA).
A major class action filed in Montreal followed within days, noting that thousands of Canadian patients were left in the dark while continuing to take contaminated pills. While our online database tracks notices issued after that initial alert, the wave of subsequent recalls continues to this day.
2019–2021: losartan, irbesartan and the azido impurity
The nitrosamine contamination investigation expanded into other angiotensin II receptor blockers (ARBs). Health Canada issued repeated recalls, including multiple lots of irbesartan, losartan and valsartan recalled for an azido impurity (2021), the Mint-Losartan/HCTZ recall, the Sandoz losartan recall, and the Sandoz valsartan recall.
Health Canada classified nitrosamines (such as NDMA and NDEA) and azido impurities as probable human carcinogens when exposure occurs above acceptable daily intake thresholds, making rapid detection and notification critical.
2022: Pfizer's Accuretic and Inderal-LA
The impurity crisis was not confined to generic sartans. In 2022, Pfizer initiated high-profile recalls of brand-name therapies, such as when Pfizer recalls Accuretic blood pressure tablets (nitrosamine) and when Pfizer recalls Inderal-LA propranolol capsules (nitrosamine).
The same manufacturing vulnerability caused ripples across other daily medications, as seen when ranitidine recalled for NDMA affected heartburn sufferers and the APO-Metformin NDMA recall impacted diabetes care.
2025–2026: the wrong pill in the bottle
Beyond chemical trace impurities, recent years have seen packaging and bottling mix-ups that present immediate danger. In February 2026, notices alerted Canadians that MAR-Amlodipine 5 mg bottles contained midodrine (Feb 2026), which drew national CBC coverage.
This followed earlier packaging mix-ups where NRA-Amlodipine bottles contained metoprolol (2025), Apo-Candesartan out-of-specification lots (2026) failed dissolution testing, a pms-Irbesartan lot mixed with irbesartan/HCTZ (Aug 2026) contained undeclared diuretic, and all lots of JAMP-Clopidogrel recalled for incorrect dose (2024).
What to do if your blood pressure medication is recalled
- Read the DIN and lot number on the label — do not go by drug name alone, as most recalls are lot-specific.
- Do not stop taking your medication without first consulting your pharmacist or doctor — Health Canada's explicit guidance emphasizes that abruptly stopping a hypertension drug poses immediate health risks.
- Contact your dispensing pharmacy for a replacement lot or generic alternative.
- Watch for follow-up notices — sartan and blood pressure recalls frequently arrive in waves across multiple brands.
Related recall guides
Get the next blood pressure drug recall by email or SMS, without checking this list again.